AJMC® in the Press, April 3, 2026

An article published by AOL referenced a study published in the November 2019 issue of The American Journal of Managed Care^® (AJMC^®). The study, “Population Health Screenings for the Prevention of Chronic Disease Progression,” found that early identification could help delay cases of end-stage kidney disease and prevent diabetes-related complications.

A study titled “A Standardized Care Pathway Increases Optimal Dialysis Starts,” published in the December 2024 issue of AJMC, was referenced in an article on Healio. The authors of the study concluded that the number of patients starting on peritoneal dialysis and optimal starts both saw significant increases after implementing a standardized transition pathway for end-stage renal disease.

An article from NCHStats referenced an article published on AJMC.com, the website of AJMC. The piece, “US Has Highest Infant, Maternal Mortality Rates Despite Most Health Care Spending,” covered a report from the Commonwealth Fund, which found that the US had the highest rates of infant and maternal mortality among high-income countries regardless of health care spending.

An article from Becker’s Health IT referenced an article published on AJMC.com. “Teledermatology Expands Patient Access, Reimbursement Opportunities” covered a session during the 2026 American Academy of Dermatology Annual Meeting, where experts explained how teledermatology could help expand patient access to care.

An article from AJMC.com titled “Diabetes Prevalence Expected to Double Globally by 2050” was referenced in an article from WDBJ7. The piece reported on research that found that the number of people with diabetes will rise from 529 million people in 2021 to at least 1.3 billion people in 2050, with no drop in age-standardized diabetes rates.

An article from FitGuru referenced a news piece published on AJMC.com. “GLP-1 RA Adherence Shows Drop-Off After 1 Year” covered findings of a significant drop-off in the usage of anti-obesity drugs after 1 year of use for first-time users, as more than half of those using the treatment had quit by follow-up.